Mirum Pharmaceuticals stock (US60471A1034): Nasdaq biotech trades just below recent highs after solid May rally

Mirum Pharmaceuticals shares on Nasdaq have eased slightly from recent highs after a strong run in May, with the United States-based rare disease specialist remaining in focus following its latest quarterly update and a robust year-to-date performance.

Mirum Pharmaceuticals shares on Nasdaq continued to consolidate near recent highs toward the end of May, with the United States-listed biotech stock trading around the high-90s USD range after a strong year-to-date rally, according to MarketBeat data as of late May 2026. The company, which focuses on therapies for rare liver diseases, remains firmly anchored in its home market with its primary listing on the Nasdaq under the ticker MIRM, giving U.S. investors straightforward access to the name.

Based on recent price information, Mirum Pharmaceuticals stock last changed hands at about USD 97 to USD 99 in late May 2026 on Nasdaq, implying a gain of more than 20% since the beginning of the year, according to MarketBeat figures as of late May 2026. The data show that the stock started the year at USD 78.99 and was quoted at USD 97.33 at the regular close on 05/26/2026, before modest moves in extended trading, underlining the company’s positive share price trajectory over the past months.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Mirum Pharmaceuticals
• Sector/industry: Biopharmaceuticals / rare disease therapeutics
• Headquarters/country: Foster City, United States
• Core markets: United States, Europe and other specialist liver disease markets
• Key revenue drivers: Commercial sales of rare pediatric and cholestatic liver disease therapies and related pipeline development milestones
• Home exchange/listing venue: Nasdaq (MIRM)
• Trading currency: USD

Mirum Pharmaceuticals: core business model

Mirum Pharmaceuticals focuses on developing and commercializing treatments for rare cholestatic and pediatric liver diseases, with revenue primarily generated from approved therapies targeting high-unmet-need patient populations and supplemented by pipeline-related income.

Industry trends and competitive position

Mirum Pharmaceuticals operates in the rare disease and specialist liver therapy segment of the broader biopharmaceutical industry, an area that continues to attract investment because payers and regulators often support targeted therapies for small but severely affected patient groups, as highlighted by sector analyses from firms such as IQVIA and Evaluate in 2025. Within this niche, Mirum competes with larger and mid-cap biopharma players focused on hepatology and rare genetic conditions, while differentiation tends to be driven by clinical data, safety and tolerability profiles, and the ability to secure reimbursement in the United States and key European markets.

The competitive landscape around liver and cholestatic diseases includes companies like Insmed, BioNTech, Roivant Sciences, Viatris and Moderna, which are cited as peers or comparables to Mirum in MarketBeat’s competitor overview as of 05/26/2026. While these peers differ in size and product focus, the comparison underscores that Mirum is positioned among innovative biotech names that pursue specialized indications, and its performance is often viewed in the context of how efficiently it converts clinical progress into commercial adoption and recurring revenue streams.

Conclusion

Mirum Pharmaceuticals stock is trading just below its late-May highs on Nasdaq after a strong year-to-date performance, underscoring sustained investor interest in the United States market. The company’s focus on rare cholestatic and pediatric liver diseases positions it within a growing biopharmaceutical segment where targeted therapies can command premium pricing and durable demand. How effectively Mirum converts its clinical and regulatory progress into long-term revenue growth will remain a central point for investors tracking the share price in the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.